CAP vs CFP | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
CAP vs CMFVP | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
CAP vs FAC | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
carboplatin followed by CAF vs CAF | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
cisplatin + epirubicin vs lonidamine + epirubicin | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
cisplatin + etoposide vs CMF | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
CMF, cisplatin, etoposide, and doxorubicin vs CMF | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
EcisF vs ECycloF | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
EPI + CIS vs EPI | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
MPEPIV or MPEMi vs CMF | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
PCb vs PE | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
VP-16+P vs paclitaxel | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |